Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, Double-Blind, Placebo-Controlled, Randomized, Multi-Center Trial With a Double-Blind Parallel-Group Extension Period to Investigate the Efficacy and Safety of Different Doses of NT 201 in the Treatment of Cervical Dystonia.

Trial Profile

Prospective, Double-Blind, Placebo-Controlled, Randomized, Multi-Center Trial With a Double-Blind Parallel-Group Extension Period to Investigate the Efficacy and Safety of Different Doses of NT 201 in the Treatment of Cervical Dystonia.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Nov 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Torticollis
  • Focus Registrational; Therapeutic Use
  • Sponsors Merz Pharmaceuticals GmbH

Most Recent Events

  • 15 Sep 2011 Results published in the Journal of the Neurological Sciences.
  • 05 Nov 2010 Results will be presented at the 71st Annual Assembly of the American Academy of Physical Medicine and Rehabilitation, according to a Merz Pharmaceuticals media release.
  • 01 Jun 2009 Primary endpoint 'Toronto-Western-Spasmodic-Torticollis-Rating-Scale' has been met.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top